Jennison Associates LLC grew its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,136,942 shares of the company's stock after purchasing an additional 184,896 shares during the period. Jennison Associates LLC owned approximately 0.56% of LifeStance Health Group worth $14,959,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently made changes to their positions in LFST. Principal Financial Group Inc. increased its position in LifeStance Health Group by 6.1% in the 3rd quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company's stock valued at $28,817,000 after buying an additional 235,316 shares in the last quarter. Park Edge Advisors LLC acquired a new stake in LifeStance Health Group in the third quarter valued at approximately $73,000. SG Americas Securities LLC increased its holdings in shares of LifeStance Health Group by 406.4% during the third quarter. SG Americas Securities LLC now owns 54,532 shares of the company's stock valued at $382,000 after acquiring an additional 43,763 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of LifeStance Health Group during the second quarter worth approximately $4,326,000. Finally, Algert Global LLC bought a new position in shares of LifeStance Health Group in the 2nd quarter worth $57,000. Institutional investors and hedge funds own 85.50% of the company's stock.
A number of brokerages have commented on LFST. UBS Group decreased their price target on shares of LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating for the company in a research note on Thursday, August 15th. Barclays boosted their target price on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an "underweight" rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $8.50.
Check Out Our Latest Analysis on LifeStance Health Group
Shares of NASDAQ:LFST opened at $7.40 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a market cap of $2.83 billion, a PE ratio of -28.46 and a beta of 1.24. The stock's fifty day simple moving average is $7.02 and its two-hundred day simple moving average is $6.27. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The company had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. During the same period last year, the firm earned ($0.17) earnings per share. The firm's revenue was up 18.9% on a year-over-year basis. As a group, analysts forecast that LifeStance Health Group, Inc. will post -0.22 EPS for the current fiscal year.
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.